SLC17A7 and Alzheimer disease: In human preclinical, end-stage AD and APP/PS1 AD model transgenic mice [115], it has been reported that the excitatory vesicular glutamate transporter 1 (vGlut1) was reduced while the density of the vesicular GABA transporter (vGAT) at presynaptic terminals was unchanged [116].